The American Journal of Managed Care

Ryplazim Marks First FDA Approval for Plasminogen Deficiency: Dr Amy Shapiro

Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, continues her discussion on plasminogen deficiency type 1 by highlighting the recent FDA approval of plasminogen (Ryplazim; ...
Monthly Prescribing Reference

First Therapy for Plasminogen Deficiency Type 1 Gets FDA Approval

Credit: Getty Images. The approval was based on data from a pivotal phase 2/3 trial that assessed Ryplazim in 15 adult and pediatric patients with hypoplasminogenemia. The Food and Drug Administration ...
The American Journal of Managed Care

Ligneous Lesions Often Misdiagnosed in Rare Plasminogen Deficiency: Dr Amy Shapiro

Amy Shapiro, MD, medical director of Indiana Hemophilia and Thrombosis Center, joined AJMC to shed light on a broadly overlooked disorder: plasminogen deficiency type-1. Plasminogen deficiency is a ...
Business Wire

Soleo Health Selected as a Specialty Pharmacy Partner of RYPLAZIM® for Plasminogen Deficiency Type 1 (PLGD-1) Treatment

FRISCO, Texas--(BUSINESS WIRE)--Soleo Health, an innovative leader and national provider of complex specialty pharmacy services for treating rare- and ultra-rare diseases, announced today it has been ...
Business Insider

Kedrion Biopharma to commercialize RYPLAZIM® (plasminogen, human-tvmh) in U.S. to address unmet need in patients with ultra-rare condition: Plasminogen Deficiency Type 1

FORT LEE, N.J., Oct. 20, 2021 /PRNewswire/ -- Kedrion Biopharma, an international biopharmaceutical company specialized in the manufacture and distribution of plasma-derived therapeutic products used ...
Longview News-Journal

Kedrion Raises Awareness Around Plasminogen Deficiency

FORT LEE, N.J., May 5, 2025 /PRNewswire/ -- Kedrion Biopharma is raising awareness for Plasminogen Deficiency (PLGD-1) with virtual, digital and in person events throughout the day on May 5. PLGD-1 is ...
News Medical

FDA approves new treatment for patients with hypoplasminogenemia

Today, the U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a ...
Healio

HISTORY project may have ‘profound impact’ on congenital plasminogen deficiency research

Please provide your email address to receive an email when new articles are posted on . Congenital plasminogen deficiency is an extremely rare disorder characterized by development of fibrinous or ...
Business Insider

Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen) for Treatment of Congenital ...

LAVAL, QC and CAMBRIDGE, England, Sept. 8, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today ...
WKRG

Kedrion Raises Awareness Around Plasminogen Deficiency

Plasminogen Deficiency Awareness Day is recognized each year on May 4, and this year we hosted events on Monday, May 5th. The goal of this awareness day is to educate the public about PLGD-1, its ...